Physician profile
Irving Friedman
NPI 1982783700
$11,849.09
in general payments reported to CMS, 2019-2025
33 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,281 · 2020: $1,109 · 2021: $1,895 · 2022: $2,727 · 2023: $1,497 · 2024: $860 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,990.91 | 2021-2025 | |
| Eisai INC. | $1,257.71 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,189.07 | 2019-2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $1,085.92 | 2019-2023 | Nuplazid |
| Ucb, INC. | $862.10 | 2019-2025 | Briviact |
| Otsuka America Pharmaceutical, INC. | $732.66 | 2023-2025 | Rexulti, Nuedexta |
| Sk Life Science, INC. | $602.49 | 2020-2024 | Xcopri |
| Lilly USA, LLC | $543.70 | 2019-2024 | Amyvid, Reyvow, Emgality |
| Avanir Pharmaceuticals, INC. | $506.12 | 2019-2022 | |
| Axsome Therapeutics, INC. | $482.85 | 2025 | Auvelity, Symbravo |
| Amgen INC. | $424.89 | 2019-2022 | |
| Biogen, INC. | $347.00 | 2021-2025 | Vumerity |
| Validus Pharmaceuticals LLC | $256.26 | 2019-2025 | Equetro, Raldesy |
| Neurelis, INC. | $223.98 | 2022-2023 | Valtoco |
| Kowa Pharmaceuticals America, INC. | $220.25 | 2022-2023 | Seglentis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $149.10 | 2019-2021 | |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart |
| Jazz Pharmaceuticals INC. | $122.06 | 2021 | |
| Vertical Pharmaceuticals, LLC | $100.91 | 2019 | |
| Pfizer INC. | $87.39 | 2019-2025 | |
| Acorda Therapeutics, INC | $68.44 | 2019 | |
| Neurocrine Biosciences, INC. | $59.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $55.73 | 2019 | |
| Bausch Health US, LLC | $54.53 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.92 | 2019-2024 | Trintellix |
| Protega Pharmaceutials INC | $45.65 | 2024 | Roxybond |
| Astrazeneca Pharmaceuticals LP | $39.58 | 2019-2020 | |
| Novo Nordisk INC | $36.95 | 2022 | |
| Currax Pharmaceuticals LLC | $33.92 | 2021 | |
| Sentynl Therapeutics, INC. | $29.83 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $20.51 | 2023 | Rytary |
| Redhill Biopharma INC. | $20.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irving Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.